Stephen Strittmatter

A world-renowned MD/Ph.D. clinician-scientist and Alzheimer’s disease expert, Steve has served on the faculty of Yale University for twenty-five years. A co-founder of the Yale Program in Cellular Neuroscience, Neurodegeneration and Repair, and Director of the Yale Alzheimer’s Disease Research Center, Steve has a passion for delivering groundbreaking translational science and treatments for Alzheimer’s Disease. Allyx is founded based on discoveries developed over the past decade of work from Steve’s academic laboratory. Steve is an experienced scientist-entrepreneur and founder of ReNetX Bio, a company focused on spinal cord injury.


Org chart

This person is not in the org chart


Teams


Offices

This person is not in any offices


Allyx Therapeutics

2 followers

Allyx Therapeutics is a clinical-stage biotechnology company aiming to develop disease-modifying therapies for Alzheimer's disease by targeting the underlying cause of synapse loss.


Industries

Employees

1-10

Links